U.S. markets closed

Viking Therapeutics, Inc. (VKTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.43-0.25 (-3.74%)
At close: 4:00PM EST

6.33 -0.10 (-1.56%)
After hours: 7:57PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.68
Bid6.39 x 900
Ask6.45 x 1400
Day's Range6.34 - 6.70
52 Week Range3.26 - 8.87
Avg. Volume1,203,896
Market Cap469.081M
Beta (5Y Monthly)2.13
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateOct 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 3 Stocks with Jaw-Dropping Growth Potential
    Motley Fool

    3 Stocks with Jaw-Dropping Growth Potential

    Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

  • Viking Therapeutics to Present at Stifel Healthcare Conference 2020
    PR Newswire

    Viking Therapeutics to Present at Stifel Healthcare Conference 2020

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 2020. The conference, which will take place November 16-18, 2020, is being conducted with a virtual format.

  • VKTX: Phase 1 Trial of VK0214 Underway…
    Zacks Small Cap Research

    VKTX: Phase 1 Trial of VK0214 Underway…

    By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update VK0214 Phase 1 Trial Initiated In September 2020, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the initiation of a Phase 1 clinical trial of VK0214, the company’s second thyroid beta (TRβ) receptor agonist. It is a randomized, double blind, placebo controlled, single ascending dose (SAD) and multiple ascending